Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

Friends, colleagues and peers pay tribute to John Martin

April 1, 2021 2:59 AM UTC
Updated on Apr 3, 2021 at 2:12 AM UTC

John Martin, the visionary leader who transformed Gilead from a fledgling antisense company into an antiviral company whose drugs turned HIV into a manageable condition and cured HCV, passed away Tuesday. He was 69.

“He is absolutely a giant of our space,” said Stelios Papadopoulos, chairman of Biogen Inc. (NASDAQ:BIIB). “He taught us how to tackle HIV. It was all of his vision. His thinking has led to where we are today, where we’ve transformed HIV AIDS from a sentence to death to a manageable chronic condition.”...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.